Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Eli Lilly has introduced successful weight loss drugs, Tirzepatide and Mounjaro, generating over $1 billion in revenue. Their dual GIP/GLP-1 receptor agonist drugs regulate blood sugar levels and appetite.